Literature DB >> 16922870

Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs.

Wolfgang Löscher1, Dieter Schmidt.   

Abstract

Development of tolerance (i.e., the reduction in response to a drug after repeated administration) is an adaptive response of the body to prolonged exposure to the drug, and tolerance to antiepileptic drugs (AEDs) is no exception. Tolerance develops to some drug effects much more rapidly than to others. The extent of tolerance depends on the drug and individual (genetic?) factors. Tolerance may lead to attenuation of side effects but also to loss of efficacy of AEDs and is reversible after discontinuation of drug treatment. Different experimental approaches are used to study tolerance in laboratory animals. Development of tolerance depends on the experimental model, drug, drug dosage, and duration of treatment, so that a battery of experimental protocols is needed to evaluate fully whether tolerance to effect occurs. Two major types of tolerance are known. Pharmacokinetic (metabolic) tolerance, due to induction of AED-metabolizing enzymes has been shown for most first-generation AEDs, and is easy to overcome by increasing dosage. Pharmacodynamic (functional) tolerance is due to "adaptation" of AED targets (e.g., by loss of receptor sensitivity) and has been shown experimentally for all AEDs that lose activity during prolonged treatment. Functional tolerance may lead to complete loss of AED activity and cross-tolerance to other AEDs. Convincing experimental evidence indicates that almost all first-, second-, and third-generation AEDs lose their antiepileptic activity during prolonged treatment, although to a different extent. Because of diverse confounding factors, detecting tolerance in patients with epilepsy is more difficult but can be done with careful assessment of decline during long-term individual patient response. After excluding confounding factors, tolerance to antiepileptic effect for most modern and old AEDs can be shown in small subgroups of responders by assessing individual or group response. Development of tolerance to the antiepileptic activity of an AED may be an important reason for failure of drug treatment. Knowledge of tolerance to AED effects as a mechanism of drug resistance in previous responders is important for patients, physicians, and scientists.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16922870     DOI: 10.1111/j.1528-1167.2006.00607.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  48 in total

1.  SV2A in epilepsy: the plot thickens.

Authors:  Graeme J Sills
Journal:  Epilepsy Curr       Date:  2010-03       Impact factor: 7.500

2.  Is epilepsy intractability predetermined or acquired?

Authors:  Bassel W Abou-Khalil
Journal:  Epilepsy Curr       Date:  2007 Jan-Feb       Impact factor: 7.500

3.  Cell and gene therapies for refractory epilepsy.

Authors:  Detlev Boison
Journal:  Curr Neuropharmacol       Date:  2007       Impact factor: 7.363

4.  Discovery of Imidazo[1,2-a]pyrazines and Pyrazolo[1,5-c]pyrimidines as TARP γ-8 Selective AMPAR Negative Modulators.

Authors:  Brad M Savall; Dongpei Wu; Devin M Swanson; Mark Seierstad; Nyantsz Wu; Jorge Vives Martinez; Beatriz García Olmos; Brian Lord; Kevin Coe; Tatiana Koudriakova; Timothy W Lovenberg; Nicholas I Carruthers; Michael P Maher; Michael K Ameriks
Journal:  ACS Med Chem Lett       Date:  2018-12-26       Impact factor: 4.345

Review 5.  The pharmacology of imepitoin: the first partial benzodiazepine receptor agonist developed for the treatment of epilepsy.

Authors:  Chris Rundfeldt; Wolfgang Löscher
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

6.  Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US.

Authors:  Tristan T Sands; Shahryar Rahdari; Michael S Oldham; Eduardo Caminha Nunes; Nicole Tilton; Maria Roberta Cilio
Journal:  CNS Drugs       Date:  2019-01       Impact factor: 5.749

Review 7.  Clobazam : in patients with Lennox-Gastaut syndrome.

Authors:  Lily P H Yang; Lesley J Scott
Journal:  CNS Drugs       Date:  2012-11       Impact factor: 5.749

Review 8.  The long-term safety of antiepileptic drugs.

Authors:  Athanasios Gaitatzis; Josemir W Sander
Journal:  CNS Drugs       Date:  2013-06       Impact factor: 5.749

9.  Topiramate in the treatment of partial and generalized epilepsy.

Authors:  Edward Faught
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

10.  Modifications of antiepileptic drugs for improved tolerability and efficacy.

Authors:  Cecilie Johannessen Landmark; Svein I Johannessen
Journal:  Perspect Medicin Chem       Date:  2008-02-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.